HOTH - Hoth Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.4000
0.0000 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.4000
Open4.4864
Bid4.4800 x 800
Ask4.6000 x 800
Day's Range4.4000 - 4.6300
52 Week Range3.2600 - 13.8800
Volume2,663
Avg. Volume17,495
Market Cap44.524M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5540
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • PR Newswire

    Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy

    Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced it has entered into a licensing agreement with North Carolina State University (NC State) to study NC State's Exon Skipping Approach for Treating Allergic Diseases.

  • PR Newswire

    Hoth Therapeutics to Attend Benchmark's 8th Annual Discovery 1x1 Conference

    NEW YORK, Nov. 18, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced that its CEO and President, Robb Knie will be attending Benchmark's 8thAnnual Discovery 1x1 Conference. For more information about the conference or to schedule a one-on-one meeting, please contact the conference coordinator. Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders.

  • PR Newswire

    Hoth Therapeutics Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication

    NEW YORK , Nov. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies ...

  • We're Not Very Worried About Hoth Therapeutics's (NASDAQ:HOTH) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Hoth Therapeutics's (NASDAQ:HOTH) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • PR Newswire

    Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment

    NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initiating a confirmatory study, related to their proprietary AEA-loaded Z-pods™ in the treatment of Cutaneous Lupus Erythematosus [CLE], a chronic autoimmune disease that affects the skin. The study is being conducted in partnership with Zylö Therapeutics to confirm that topical administration of Hoth's AEA-loaded Z-pods™ inhibits the development of CLE lesions in a well-established animal model of lupus.

  • GlobeNewswire

    Four Innovators Targeting Multi-Billion-Dollar Market Opportunities in: E-Commerce, Healthcare Augmented Reality, and Cannabis

    NEW YORK, Oct. 16, 2019 -- Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, and conference presentation.

  • PR Newswire

    Hoth Therapeutics to Present at the Dawson James 5th Annual Small Cap Growth Conference

    NEW YORK , Oct. 15, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic ...

  • PR Newswire

    Hoth Therapeutics Makes Donation to National Eczema Association in Sponsorship of "National Eczema Awareness Month"

    NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has made a donation to the National Eczema Association in order to bring continued awareness to National Eczema Awareness Month this October. Atopic dermatitis (AD) is a chronic inflammatory skin disease that presents a significant burden on health-care resources and patients' quality of life.

  • PR Newswire

    Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema

    NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that they have completed Phase I of their In-Life dose escalation study. The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. "Management is pleased that our BioLexa Platform continues to demonstrate an impressive safety profile during its testing phase," said, Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics.

  • GlobeNewswire

    Wall Street Reporter presents: “NEXT SUPER STOCK - Live!” Investor Conference September 26, 2019

    NEW YORK, Sept. 25, 2019 -- Wall Street Reporter will be hosting the “NEXT SUPER STOCK - Live!” livestream online-only investor conference on Thursday September 26, 2019 from.

  • GlobeNewswire

    Emerging Markets Report: Looking Beyond Skin Deep

    Today’s featured company Hoth Therapeutics, Inc. (HOTH) makes its claim in the marketplace of Life Science ideas with an array of skin-related products that span a large portion of the dermalogical spectrum. As a relatively new issue following its recent IPO, many investors and institutions are focused on the share price, when really, a deeper look reveals a Company entrenched in some of the largest sectors of the health care market, leverage against competition, and a highly unique treatment approach for its lead product BioLexa which looks to service the massive eczema market. A recent research report from Diamond Equity Research hammers home the present and future potential for Hoth.

  • PR Newswire

    Hoth Therapeutics, Inc. to Present at Diamond Equity Research Emerging Growth Invitational

    NEW YORK , Sept. 24, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic ...

  • GlobeNewswire

    New Ideas for Billion Dollar Markets: Emerging Leaders in Cannabis, Augmented Reality, and Healthcare

    CEO Interviews with: HEXO, HOTH, MDCL, NEXCFNews & VIDEO from Investor Conferences: NEXCF, MDCL NEW YORK, Sept. 18, 2019 -- Wall Street Reporter, the trusted name in.

  • GlobeNewswire

    Next Super Stock conference presenters: CYDY, MDCL, HOTH, NEXCF delivering results, and positioned for transformational growth in coming months

    NEW YORK, Sept. 16, 2019 -- Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, video presentations, and news.

  • ACCESSWIRE

    Diamond Equity Research Initiates Coverage on Hoth Therapeutics, Inc. (NASDAQ: HOTH)

    NEW YORK, NY / ACCESSWIRE / September 16, 2019 / Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies has initiated coverage of Hoth Therapeutics, Inc. (NASDAQ:HOTH). The in-depth 24-page initiation report includes detailed information on Hoth's business model, services, industry, valuation, management, and risks. The full research report is available here.

  • PR Newswire

    Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference

    NEW YORK, Sept. 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that Robb Knie, Chief Executive Officer, will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference in New York on September 10, 20919 and the RESI 2019 Conference in Boston on September 11, 2019. Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

  • PR Newswire

    Hoth Therapeutics, Inc. Issues Letter to Shareholders

    NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound disorders, today issued a letter to shareholders.

  • PR Newswire

    Hoth Therapeutics and Zylö Therapeutics Finalize Agreement

    NEW YORK, Aug. 21, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound disorders, today announced it has entered into a definitive partnership agreement with Zylö Therapeutics to develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus [CLE], a chronic autoimmune disease that affects the skin.

  • What Kind Of Shareholders Own Hoth Therapeutics, Inc. (NASDAQ:HOTH)?
    Simply Wall St.

    What Kind Of Shareholders Own Hoth Therapeutics, Inc. (NASDAQ:HOTH)?

    A look at the shareholders of Hoth Therapeutics, Inc. (NASDAQ:HOTH) can tell us which group is most powerful...

  • PR Newswire

    Hoth Therapeutics, Inc. Announces Positive Results from Pilot Study of BioLexa on Diabetic Skin Ulcers

    This pilot study was designed to establish foundational protocols for assessing effectiveness of a therapeutic compound developed by Hoth Therapeutics, the BioLexa Platform, for accelerating and improving wound healing in the context of acute and chronic diabetic ulcers, using an animal model of impaired wound healing developed at Massachusetts General Hospital (MGH).

  • PR Newswire

    Hoth Therapeutics, Inc. Expands Working Relationship with the George Washington University and Enters Exclusive License Option Agreement

    NEW YORK, July 15, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that it has entered into an exclusive license option agreement with the George Washington University (GW) pertaining to its intellectual property on the use of Aprepitant in treating skin-related and other side effects from drugs used to treat cancer. Under the terms of the agreement, Hoth has an option to exclusively license two U.S. patents (Nos.

  • PR Newswire

    Hoth Therapeutics, Inc. Enters into Sponsored Research Agreement with the George Washington University

    NEW YORK, June 27, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that it has entered into a sponsored research agreement with the George Washington University (GW) to explore the potential use of Aprepitant for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients.

  • PR Newswire

    Hoth Therapeutics to Present to Investors at the Union League of Philadelphia

    NEW YORK, June 13, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that its Chief Executive Officer, Mr. Robb Knie will be presenting on June 26, 2019 at the Union League of Philadelphia. The Union League of Philadelphia is ranked the number one City Club in the Country. In attendance will be the Broad Street Angels ("BSA"), a Union League of Philadelphia affinity club comprised of approximately 100 accredited investors. The BSA is a member-led investors network focusing on early stage, high-growth businesses in the Mid-Atlantic.

  • PR Newswire

    Hoth Therapeutics to Begin Production of BioLexa Therapeutic for Upcoming Toxicology and Clinical Trials

    NEW YORK, June 10, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as dermatological and chronic wound disorders, today announced it has signed contracts with providers for production of their BioLexa therapeutic, in preparation for upcoming toxicology and clinical studies. Hoth has begun preparations for the testing of its formulation for both active and vehicle stability.  The Company has engaged the services of both Particle Sciences, Inc. and Regis Technologies, Inc., in order to fulfill the necessary formulation and production of both Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) of its biopharmaceutical.  The BioLexa Platform is a proprietary, patented antimicrobial therapy designed for the treatment of atopic dermatitis.

  • PR Newswire

    Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution

    NEW YORK, June 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as dermatological and chronic wound disorders, today announced the formation of its subsidiary, Hoth Therapeutics Australia Pty Ltd, in anticipation to perform clinical trials for atopic dermatitis.